Companies / Consumer Staples
KDP
Keurig Dr Pepper
Soft Drinks & Non-alcoholic Beverages
Soft Drinks & Non-alcoholic BeveragesAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health52
Growth48
Profitability65
Cash generation47
Balance sheet19
Dilution control81
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-30)70.6%Revenue growth (FY)8.2%Revenue CAGR (3y)5.7%Gross margin54.2%Operating margin21.5%Net margin12.5%Free cash flow margin9.1%R&D / revenue0.4%Stock comp / revenue0.6%Net debt / operating cash flow6.48xCurrent ratio0.64Diluted share count change-0.4%
| Fiscal year ending | FY 2021-12 | FY 2022-12 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $12.7B | $14.1B | $14.8B | $15.4B | $16.6B |
| Gross profit | $7.0B | $7.3B | $8.1B | $8.5B | $9.0B |
| Operating income | $2.9B | $2.6B | $3.2B | $2.6B | $3.6B |
| Net income | $2.1B | $1.4B | $2.2B | $1.4B | $2.1B |
| Operating cash flow | $2.9B | $2.8B | $1.3B | $2.2B | $2.0B |
| Capital expenditure | $423M | $353M | $425M | $563M | $486M |
| Free cash flow | $2.5B | $2.5B | $904M | $1.7B | $1.5B |
| R&D | $66M | $65M | $66M | $70M | $70M |
| Stock-based comp | $88M | $52M | $116M | $98M | $97M |
| Buybacks | $0 | $379M | $706M | $1.1B | $9M |
| Dividends | $955M | $1.1B | $1.1B | $1.2B | $1.2B |
| Cash | $567M | $535M | $267M | $510M | $1.0B |
| Total debt | $11.9B | $12.1B | $11.1B | $13.9B | $13.9B |
| Equity | $25.0B | $25.1B | $25.7B | $24.2B | $25.5B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.